GlassScriptPhysician profile
Zachary Leblanc
NPI 1386888634
$54,763.35
in general payments reported to CMS, 2019-2025
37 companies · $22K in 2025
The $22K reported for 2025 was more than what 92% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $301 · 2021: $429 · 2022: $484 · 2023: $13K · 2024: $18K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Travel and Lodging: $13K · Consulting Fee: $9,391 · Food and Beverage: $4,347 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,803.00 |
| Travel and Lodging | $13,192.68 |
| Consulting Fee | $9,390.68 |
| Food and Beverage | $4,347.13 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $50,345.95 | 2019-2025 | |
| Genetix Biotherapeutics INC | $863.79 | 2023-2025 | Lyfgenia |
| Jazz Pharmaceuticals INC. | $502.98 | 2019-2025 | |
| Novo Nordisk INC | $431.88 | 2019-2025 | Alhemo |
| Novartis Pharmaceuticals Corporation | $322.22 | 2019-2024 | |
| Genzyme Corporation | $253.10 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $174.41 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $141.51 | 2019-2024 | Ultomiris, Koselugo |
| Csl Behring | $133.39 | 2019-2023 | Hemgenix |
| Incyte Corporation | $124.93 | 2025 | Niktimvo |
| Octapharma USA, INC. | $124.78 | 2023-2024 | Nuwiq, Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Sanofi-Aventis U.S. LLC | $121.82 | 2025 | |
| Mesoblast, INC. | $119.90 | 2025 | Ryoncil |
| Global Blood Therapeutics, INC. | $112.36 | 2020-2021 | |
| Bioverativ Therapeutics INC. | $110.26 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $100.15 | 2019 | |
| Btg International INC. | $94.61 | 2020-2023 | |
| Emmaus Medical, INC. | $71.95 | 2019-2021 | |
| Pfizer INC. | $68.67 | 2023-2024 | |
| Y-Mabs Therapeutics, INC. | $62.18 | 2023-2025 | Danyelza |
| Uswm, LLC | $56.03 | 2024-2025 | Iwilfin |
| Eurofins Viracor, LLC | $51.87 | 2020-2021 | |
| Hema Biologics, LLC | $50.32 | 2023 | Sevenfact |
| Seagen INC. | $41.80 | 2023 | Adcetris |
| Genentech USA, INC. | $39.69 | 2023-2024 | Hemlibra |
| Astrazeneca Pharmaceuticals LP | $32.74 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $29.71 | 2023 | |
| Fennec Pharmaceuticals, INC. | $27.90 | 2023 | Pedmark |
| Apellis Pharmaceuticals, INC. | $25.45 | 2025 | Empaveli |
| Medunik USA INC. | $25.18 | 2025 | Siklos |
| Chiesi USA, INC. | $19.48 | 2020 | |
| Rare Disease Therapeutics, INC. | $18.36 | 2019 | |
| Adaptive Biotechnologies Corporation | $18.28 | 2024 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $16.83 | 2021 | |
| Shire North American Group INC | $16.77 | 2019 | |
| Silvergate Pharmaceuticals, INC. | $12.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Leblanc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.